Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: Angelo who wrote (2488)	5/26/1998 11:25:00 AM
From: GREATMOOD	Read Replies (3) \| Respond to of 3725

Imatron Receives Multiple Ultrafast CT Scanner Order From MedCath Inc.; First Two Installations Planned for the Arizona Heart Institute and Heart Hospital of Austin SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 26, 1998-- Imatron Inc. (Nasdaq: IMAT) said today that it has received an initial order for two Ultrafast CT(R) scanners from MedCath Inc., a health service provider which develops heart hospitals and specialized cardiac care facilities in the United States. The purchase agreement between the companies, which is in effect until December 31, 2001, also provides for additional sales of future Ultrafast CT scanning systems. The first scanner of the order will ship to the Arizona Heart Institute, Phoenix, Arizona, in the current quarter, with the second delivery to The Heart Hospital of Austin, Texas, to follow in third quarter 1998. S. Lewis Meyer, Imatron's President and Chief Executive Officer, stated, "This initial order and multiple system purchase agreement between Imatron and MedCath Inc. is another validation of our newly established domestic sales team. The Arizona Heart Institute is a prestigious coronary care facility recognized for its pioneering efforts in the delivery of quality cardiac care. The Heart Hospital of Austin is the first of what we hope to be many Ultrafast CT scanner placements in MedCath's growing nationwide network of heart hospitals. We expect to place as many as four units in MedCath facilities over the next twelve months." According to Tom Hearn, President of MedCath's Diagnostics Division, "The unprecedented sensitivity and accuracy of Imatron's Ultrafast CT scanner for coronary artery disease screening is completely consistent with MedCath's goal of providing state of the art technologies and facilities for the diagnosis and treatment of coronary artery disease." Imatron Inc. is primarily engaged in designing, manufacturing, marketing, and supporting high performance computed tomography (CT) scanners based on the Company's proprietary scanning electron beam technology. Ultrafast CT(R) is a registered trademark of Imatron. Imatron's Ultrafast CT scanner is now in use at major medical centers around the world, including The Mayo Clinic, University of Iowa, National Institutes of Health, UCLA, Stanford University, University of Illinois, The Royal Brompton Hospital in London, Tokyo University Hospital, Beijing Hospital and the National University Hospital of Singapore. Imatron's HeartScan Imaging Inc. subsidiary provides Coronary Artery Disease Risk Assessment diagnostic services in a nationwide network of clinics. -0- Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements that are based on current expectations and estimates about the industry in which Imatron operates, the estimated impact of certain technological advances, the estimated impact of published research studies on scanner sales and procedures, as well as management's beliefs and assumptions. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. The factors that could cause actual results to differ materially include, among others: failed clinical demonstration of certain asserted technological advantages and diagnostic capabilities; reliance on product distributors; competition in the diagnostic imaging market; failure to improve product reliability or introduce new product models and enhancements; delays in production and difficulty in obtaining components and sub-assemblies from limited sources of supply; inability to meet cash-on-delivery or prepayment terms from vendors; determinations by regulatory and administrative government authorities; patent expiration and denial of patent applications; the high cost of the scanner as compared to commercially available CT scanners; and the risk factors listed from time to time in the Company's Securities and Exchange Commission reports, including their reports on Form 10-K for their current fiscal year. --30--RPL/la* MCB/la JP/la CONTACT: Imatron Inc., South San Francisco S. Lewis Meyer, Gary Brooks or Lisa Kimberlin 650/583-9964 or Sitrick and Company Jeffrey Lloyd 310/788-2850